Douglas G. McNeel - Publications

Affiliations: 
Cancer Biology University of Wisconsin, Madison, Madison, WI 
Area:
Oncology, Molecular Biology, Immunology

168 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2024 Muralidhar A, Hernandez R, Morris ZS, Comas Rojas H, Bio Idrissou M, Weichert JP, McNeel DG. Myeloid-derived suppressor cells attenuate the antitumor efficacy of radiopharmaceutical therapy using Y-NM600 in combination with androgen deprivation therapy in murine prostate tumors. Journal For Immunotherapy of Cancer. 12. PMID 38663936 DOI: 10.1136/jitc-2023-008760  0.403
2023 Jeon D, Hill E, McNeel DG. Toll-like receptor agonists as cancer vaccine adjuvants. Human Vaccines & Immunotherapeutics. 20: 2297453. PMID 38155525 DOI: 10.1080/21645515.2023.2297453  0.401
2023 McNeel DG, Emamekhoo H, Eickhoff JC, Kyriakopoulos CE, Wargowski E, Tonelli TP, Johnson LE, Liu G. Phase 2 trial of a DNA vaccine (pTVG-HP) and nivolumab in patients with castration-sensitive non-metastatic (M0) prostate cancer. Journal For Immunotherapy of Cancer. 11. PMID 38101860 DOI: 10.1136/jitc-2023-008067  0.514
2023 Rastogi I, McNeel DG. B cells require licensing by dendritic cells to serve as primary antigen-presenting cells for plasmid DNA. Oncoimmunology. 12: 2212550. PMID 37205983 DOI: 10.1080/2162402X.2023.2212550  0.302
2023 Chi KN, Fleshner N, Chiuri VE, Van Bruwaene S, Hafron J, McNeel DG, De Porre P, Maul RS, Daksh M, Zhong X, Mason GE, Tutrone RF. Niraparib with Abiraterone Acetate and Prednisone for Metastatic Castration-Resistant Prostate Cancer: Phase II QUEST Study Results. The Oncologist. PMID 36994854 DOI: 10.1093/oncolo/oyad008  0.372
2023 Rastogi I, Muralidhar A, McNeel DG. Vaccines as treatments for prostate cancer. Nature Reviews. Urology. 1-16. PMID 36879114 DOI: 10.1038/s41585-023-00739-w  0.546
2023 Muralidhar A, Potluri HK, Jaiswal T, McNeel DG. Targeted Radiation and Immune Therapies-Advances and Opportunities for the Treatment of Prostate Cancer. Pharmaceutics. 15. PMID 36678880 DOI: 10.3390/pharmaceutics15010252  0.476
2022 Rodems TS, Heninger E, Stahlfeld CN, Gilsdorf CS, Carlson KN, Kircher MR, Singh A, Krueger TEG, Beebe DJ, Jarrard DF, McNeel DG, Haffner MC, Lang JM. Reversible epigenetic alterations regulate class I HLA loss in prostate cancer. Communications Biology. 5: 897. PMID 36050516 DOI: 10.1038/s42003-022-03843-6  0.4
2022 Potluri HK, Ferreira CA, Grudzinski J, Massey C, Aluicio-Sarduy E, Engle JW, Kwon O, Marsh IR, Bednarz BP, Hernandez R, Weichert JP, McNeel DG. Antitumor efficacy of Y-NM600 targeted radionuclide therapy and PD-1 blockade is limited by regulatory T cells in murine prostate tumors. Journal For Immunotherapy of Cancer. 10. PMID 36002185 DOI: 10.1136/jitc-2022-005060  0.429
2022 Terrisse S, Goubet AG, Ueda K, Thomas AM, Quiniou V, Thelemaque C, Dunsmore G, Clave E, Gamat-Huber M, Yonekura S, Ferrere G, Rauber C, Pham HP, Fahrner JE, Pizzato E, ... ... McNeel DG, et al. Immune system and intestinal microbiota determine efficacy of androgen deprivation therapy against prostate cancer. Journal For Immunotherapy of Cancer. 10. PMID 35296557 DOI: 10.1136/jitc-2021-004191  0.421
2022 McNeel DG, Eickhoff JC, Wargowski E, Johnson LE, Kyriakopoulos CE, Emamekhoo H, Lang JM, Brennan MJ, Liu G. Phase 2 trial of T-cell activation using MVI-816 and pembrolizumab in patients with metastatic, castration-resistant prostate cancer (mCRPC). Journal For Immunotherapy of Cancer. 10. PMID 35277461 DOI: 10.1136/jitc-2021-004198  0.459
2022 Potluri HK, Ng TL, Newton MA, McNeel DG. GM-CSF elicits antibodies to tumor-associated proteins when used as a prostate cancer vaccine adjuvant. Cancer Immunology, Immunotherapy : Cii. PMID 35133464 DOI: 10.1007/s00262-022-03150-3  0.504
2021 Drake CG, Pachynski RK, Subudhi SK, McNeel DG, Antonarakis ES, Bauer TM, Lauer P, Brockstedt D, Patricia D, Wade M, Zudaire E, Bandyopadhyay N, Parasrampuria DA, Girgis S, Mason GE, et al. Safety and preliminary immunogenicity of JNJ-64041809, a live-attenuated, double-deleted Listeria monocytogenes-based immunotherapy, in metastatic castration-resistant prostate cancer. Prostate Cancer and Prostatic Diseases. PMID 34257408 DOI: 10.1038/s41391-021-00402-8  0.462
2020 Potluri HK, Ng TL, Newton MA, Zhang J, Maher CA, Nelson PS, McNeel DG. Antibody profiling of patients with prostate cancer reveals differences in antibody signatures among disease stages. Journal For Immunotherapy of Cancer. 8. PMID 33335027 DOI: 10.1136/jitc-2020-001510  0.415
2020 Gamat-Huber M, Jeon D, Johnson LE, Moseman JE, Muralidhar A, Potluri HK, Rastogi I, Wargowski E, Zahm CD, McNeel DG. Treatment Combinations with DNA Vaccines for the Treatment of Metastatic Castration-Resistant Prostate Cancer (mCRPC). Cancers. 12. PMID 33008010 DOI: 10.3390/cancers12102831  0.478
2020 Kyriakopoulos CE, Eickhoff J, Ferrari AC, Schweizer MT, Wargowski E, Olson BM, McNeel DG. Multicenter Phase 1 Trial of a DNA Vaccine Encoding the Androgen Receptor Ligand Binding Domain (pTVG-AR, MVI-118) in Patients with Metastatic Prostate Cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 32513836 DOI: 10.1158/1078-0432.Ccr-20-0945  0.566
2020 Gamat-Huber M, McNeel DG. Androgen deprivation as a tumour-immunomodulating treatment. Nature Reviews. Urology. PMID 32355324 DOI: 10.1038/S41585-020-0328-6  0.466
2020 Madan RA, Antonarakis ES, Drake CG, Fong L, Yu EY, McNeel DG, Lin DW, Chang NN, Sheikh NA, Gulley JL. Putting the Pieces Together: Completing the Mechanism of Action Jigsaw for Sipuleucel-T. Journal of the National Cancer Institute. PMID 32145020 DOI: 10.1093/Jnci/Djaa021  0.546
2020 Sullivan JA, AlAdra DP, Olson BM, McNeel DG, Burlingham WJ. Infectious Tolerance as Seen With 2020 Vision: The Role of IL-35 and Extracellular Vesicles Frontiers in Immunology. 11. DOI: 10.3389/Fimmu.2020.01867  0.325
2020 Emamekhoo H, Kyriakopoulos C, Liu G, McNeel DG. Phase II trial of a DNA vaccine encoding prostatic acid phosphatase (pTVG-HP) and nivolumab (Nivo) in patients (pts) with nonmetastatic, PSA-recurrent prostate cancer (PCa). Journal of Clinical Oncology. 38: TPS273-TPS273. DOI: 10.1200/Jco.2020.38.6_Suppl.Tps273  0.482
2020 Potluri HK, Hernandez R, Zahm CD, Grudzinski J, Massey C, Weichert J, McNeel DG. Abstract 2262: Low-dose targeted radionuclide therapy has favorable local and systemic effects on immune populations in a murine prostate cancer model Immunology. DOI: 10.1158/1538-7445.Am2020-2262  0.478
2019 McNeel DG, Eickhoff JC, Johnson LE, Roth AR, Perk TG, Fong L, Antonarakis ES, Wargowski E, Jeraj R, Liu G. Phase II Trial of a DNA Vaccine Encoding Prostatic Acid Phosphatase (pTVG-HP [MVI-816]) in Patients With Progressive, Nonmetastatic, Castration-Sensitive Prostate Cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO1901701. PMID 31644357 DOI: 10.1200/Jco.19.01701  0.592
2019 Zahm CD, Johnson LE, McNeel DG. Increased indoleamine 2,3-dioxygenase activity and expression in prostate cancer following targeted immunotherapy. Cancer Immunology, Immunotherapy : Cii. PMID 31606777 DOI: 10.1007/S00262-019-02394-W  0.583
2019 Ehlerding EB, Lee HJ, Barnhart TE, Jiang D, Kang L, McNeel DG, Engle JW, Cai W. Noninvasive imaging and quantification of radiotherapy-induced PD-L1 upregulation with Zr-Df-atezolizumab. Bioconjugate Chemistry. PMID 30973703 DOI: 10.1021/Acs.Bioconjchem.9B00178  0.322
2019 Scarpelli M, Zahm C, Perlman S, McNeel DG, Jeraj R, Liu G. FLT PET/CT imaging of metastatic prostate cancer patients treated with pTVG-HP DNA vaccine and pembrolizumab. Journal For Immunotherapy of Cancer. 7: 23. PMID 30700328 DOI: 10.1186/S40425-019-0516-1  0.484
2019 Drake CG, Pachynski RK, Subudhi SK, McNeel DG, Antonarakis ES, Bauer TM, Patricia D, Wade M, Zudaire E, Mason G, Knoblauch RE, Stone NL, Infante JR, Gottardis M, Fong L. Safety and preliminary immunogenicity of JNJ-64041809, a live attenuated, double-deleted Listeria monocytogenes-based immunotherapy, in metastatic castration-resistant prostate cancer (mCRPC). Journal of Clinical Oncology. 37: e16509-e16509. DOI: 10.1200/Jco.2019.37.15_Suppl.E16509  0.414
2019 Liu G, Fong L, Antonarakis ES, Eickhoff JC, Wargowski EG, Johnson LE, Jeraj R, McNeel DG. Randomized phase II trial of a DNA vaccine encoding prostatic acid phosphatase (pTVG-HP) versus GM-CSF adjuvant in patients with PSA-recurrent prostate cancer. Journal of Clinical Oncology. 37: 5037-5037. DOI: 10.1200/Jco.2019.37.15_Suppl.5037  0.498
2019 Conlon K, Leidner R, McNeel D, Gupta S, Wang-Gillam A, Waldmann TA, Pavlakis G, Dostalek M, Kurtulus S, Chowdhury NR, O'Keeffe J, Parikh NS, Thompson JA. Abstract CT082: Phase (Ph) I/Ib study of NIZ985 with and without spartalizumab (PDR001) in patients (pts) with metastatic/unresectable solid tumors Cancer Research. 79. DOI: 10.1158/1538-7445.Sabcs18-Ct082  0.326
2018 Johnson LE, Brockstedt D, Leong M, Lauer P, Theisen E, Sauer JD, McNeel DG. Heterologous vaccination targeting prostatic acid phosphatase (PAP) using DNA and vaccines elicits superior anti-tumor immunity dependent on CD4+ T cells elicited by DNA priming. Oncoimmunology. 7: e1456603. PMID 30221049 DOI: 10.1080/2162402X.2018.1456603  0.592
2018 Zahm CD, Colluru VT, McIlwain SJ, Ong IM, McNeel DG. TLR Stimulation During T-cell Activation Lowers PD-1 Expression on CD8+ T Cells. Cancer Immunology Research. PMID 30201735 DOI: 10.1158/2326-6066.Cir-18-0243  0.42
2018 McNeel DG, Eickhoff JC, Wargowski E, Zahm C, Staab MJ, Straus J, Liu G. Concurrent, but not sequential, PD-1 blockade with a DNA vaccine elicits anti-tumor responses in patients with metastatic, castration-resistant prostate cancer. Oncotarget. 9: 25586-25596. PMID 29876010 DOI: 10.18632/Oncotarget.25387  0.606
2018 Wargowski E, Johnson LE, Eickhoff JC, Delmastro L, Staab MJ, Liu G, McNeel DG. Prime-boost vaccination targeting prostatic acid phosphatase (PAP) in patients with metastatic castration-resistant prostate cancer (mCRPC) using Sipuleucel-T and a DNA vaccine. Journal For Immunotherapy of Cancer. 6: 21. PMID 29534736 DOI: 10.1186/S40425-018-0333-Y  0.643
2017 McNeel DG. Therapeutic Cancer Vaccines: How Much Closer Are We? Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy. PMID 29285731 DOI: 10.1007/S40259-017-0257-Y  0.543
2017 Kelly M, McNeel D, Fisch P, Malkovsky M. Immunological considerations underlying heat shock protein-mediated cancer vaccine strategies. Immunology Letters. 193: 1-10. PMID 29129721 DOI: 10.1016/J.Imlet.2017.11.001  0.415
2017 Olson BM, Gamat M, Seliski J, Sawicki T, Jeffery J, Ellis L, Drake CG, Weichert J, McNeel DG. Prostate cancer cells express more androgen receptor (AR) following androgen deprivation, improving recognition by AR-specific T cells. Cancer Immunology Research. PMID 29051161 DOI: 10.1158/2326-6066.Cir-16-0390  0.585
2017 England CG, Jiang D, Ehlerding EB, Rekoske BT, Ellison PA, Hernandez R, Barnhart TE, McNeel DG, Huang P, Cai W. (89)Zr-labeled nivolumab for imaging of T-cell infiltration in a humanized murine model of lung cancer. European Journal of Nuclear Medicine and Molecular Imaging. PMID 28821924 DOI: 10.1007/S00259-017-3803-4  0.391
2017 Gamat M, McNeel DG. Androgen deprivation and immunotherapy for the treatment of prostate cancer. Endocrine-Related Cancer. PMID 28814451 DOI: 10.1530/Erc-17-0145  0.551
2017 Johnson LE, Olson BM, McNeel DG. Pretreatment antigen-specific immunity and regulation - association with subsequent immune response to anti-tumor DNA vaccination. Journal For Immunotherapy of Cancer. 5: 56. PMID 28725429 DOI: 10.1186/s40425-017-0260-3  0.516
2017 Johnson LE, Olson BM, McNeel DG. Pretreatment antigen-specific immunity and regulation - association with subsequent immune response to anti-tumor DNA vaccination. Journal For Immunotherapy of Cancer. 5: 56. PMID 28716080 DOI: 10.1186/S40425-017-0260-3  0.594
2017 Zahm CD, Colluru V, McNeel DG. Vaccination with High-Affinity Epitopes Impairs Antitumor Efficacy by Increasing PD-1Expression on CD8+ T Cells. Cancer Immunology Research. PMID 28634215 DOI: 10.1158/2326-6066.Cir-16-0374  0.438
2017 Ehlerding EB, England CG, Majewski RL, Valdovinos HF, Jiang D, Liu G, McNeel DG, Nickles RJ, Cai W. ImmunoPET imaging of CTLA-4 expression in mouse models of non-small cell lung cancer. Molecular Pharmaceutics. PMID 28388076 DOI: 10.1021/Acs.Molpharmaceut.7B00056  0.336
2017 Zahm CD, Colluru VT, McNeel DG. DNA Vaccines for Prostate Cancer. Pharmacology & Therapeutics. PMID 28185916 DOI: 10.1016/J.Pharmthera.2017.02.016  0.519
2017 Olson BM, Bradley ES, Sawicki T, Zhong W, Ranheim EA, Bloom JE, Colluru VT, Johnson LE, Rekoske BT, Eickhoff JC, McNeel DG. Safety and Immunological Efficacy of a DNA Vaccine Encoding the Androgen Receptor Ligand-Binding Domain (AR-LBD). The Prostate. PMID 28181678 DOI: 10.1002/Pros.23321  0.575
2017 McNeel DG, Eickhoff JC, Jeraj R, Staab MJ, Straus J, Rekoske B, Liu G. DNA vaccine with pembrolizumab to elicit antitumor responses in patients with metastatic, castration-resistant prostate cancer (mCRPC). Journal of Clinical Oncology. 35: 168-168. DOI: 10.1200/Jco.2017.35.7_Suppl.168  0.624
2016 McNeel DG, Bander NH, Beer TM, Drake CG, Fong L, Harrelson S, Kantoff PW, Madan RA, Oh WK, Peace DJ, Petrylak DP, Porterfield H, Sartor O, Shore ND, Slovin SF, et al. The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of prostate carcinoma. Journal For Immunotherapy of Cancer. 4: 92. PMID 28031820 DOI: 10.1186/S40425-016-0198-X  0.547
2016 McNeel DG. TCR diversity - a universal cancer immunotherapy biomarker? Journal For Immunotherapy of Cancer. 4: 69. PMID 27879971 DOI: 10.1186/S40425-016-0175-4  0.489
2016 Colluru VT, Zahm CD, McNeel DG. Mini-intronic plasmid vaccination elicits tolerant LAG3(+) CD8(+) T cells and inferior antitumor responses. Oncoimmunology. 5: e1223002. PMID 27853647 DOI: 10.1080/2162402X.2016.1223002  0.52
2016 Heninger E, Krueger TE, Thiede SM, Sperger JM, Byers BL, Kircher MR, Kosoff D, Yang B, Jarrard DF, McNeel DG, Lang JM. Inducible expression of cancer-testis antigens in human prostate cancer. Oncotarget. PMID 27769045 DOI: 10.18632/Oncotarget.12711  0.588
2016 Colluru VT, McNeel DG. B lymphocytes as direct antigen-presenting cells for anti-tumor DNA vaccines. Oncotarget. PMID 27661128 DOI: 10.18632/Oncotarget.12178  0.485
2016 Rekoske BT, McNeel DG. Immunotherapy for prostate cancer: False promises or true hope? Cancer. PMID 27649312 DOI: 10.1002/Cncr.30250  0.546
2016 England CG, Ehlerding EB, Hernandez R, Rekoske BT, Graves SA, Sun H, Liu G, McNeel DG, Barnhart TE, Cai W. Preclinical Pharmacokinetics and Biodistribution Studies of 89Zr-labeled Pembrolizumab. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. PMID 27493273 DOI: 10.2967/Jnumed.116.177857  0.357
2016 Rekoske BT, Olson BM, McNeel DG. Antitumor vaccination of prostate cancer patients elicits PD-1/PD-L1 regulated antigen-specific immune responses. Oncoimmunology. 5: e1165377. PMID 27471641 DOI: 10.1080/2162402X.2016.1165377  0.529
2016 Ehlerding EB, England CG, McNeel DG, Cai W. Molecular Imaging of Immunotherapy Targets in Cancer. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. PMID 27469363 DOI: 10.2967/Jnumed.116.177493  0.384
2016 Bloom JE, McNeel DG. SSX2 regulates focal adhesion but does not drive the epithelial to mesenchymal transition in prostate cancer. Oncotarget. PMID 27276714 DOI: 10.18632/Oncotarget.9802  0.538
2016 Choueiri TK, Fishman M, Escudier B, McDermott DF, Drake CG, Kluger HM, Stadler WM, Perez-Gracia JL, McNeel DG, Curti BD, Harrison MR, Plimack ER, Appleman L, Fong L, Albiges L, et al. Immunomodulatory Activity of Nivolumab in Metastatic Renal Cell Carcinoma. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 27169994 DOI: 10.1158/1078-0432.Ccr-15-2839  0.313
2016 Liu G, Fong L, Antonarakis ES, Eickhoff JC, Johnson LE, McNeel DG. Randomized phase II trial of a DNA vaccine encoding prostatic acid phosphatase (PAP) versus GM-CSF adjuvant in patients with biochemically recurrent prostate cancer. Journal of Clinical Oncology. 34: TPS3114-TPS3114. DOI: 10.1200/Jco.2016.34.15_Suppl.Tps3114  0.578
2016 Ager C, Reilley M, Nicholas C, Bartkowiak T, Jaiswal A, Curran M, Albershardt TC, Bajaj A, Archer JF, Reeves RS, Ngo LY, Berglund P, ter Meulen J, Denis C, Ghadially H, ... ... McNeel DG, et al. 31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part two Journal For Immunotherapy of Cancer. 4. DOI: 10.1186/S40425-016-0173-6  0.337
2016 McNeel DG, Fong L, Antonarakis ES, Liu G. Abstract B147: Randomized phase II trial of a DNA vaccine encoding prostatic acid phosphatase (PAP) in patients with recurrent prostate cancer (NCT01341652) Cancer Immunology Research. 4. DOI: 10.1158/2326-6074.Cricimteatiaacr15-B147  0.618
2016 Johnson LE, Olson BM, McNeel DG. Abstract 3945: Antigen-specific immunity and regulation as predictive biomarkers for anti-tumor vaccination Cancer Research. 76: 3945-3945. DOI: 10.1158/1538-7445.Am2016-3945  0.479
2016 Zahm CD, McNeel DG. Abstract 2362: Optimizing prostate cancer immunotherapy by reducing vaccine induced PD-1 expression Cancer Research. 76: 2362-2362. DOI: 10.1158/1538-7445.Am2016-2362  0.493
2016 Colluru VT, McNeel DG. Abstract 2360: GP350 containing exosomes as DNA vaccine carriers Cancer Research. 76: 2360-2360. DOI: 10.1158/1538-7445.Am2016-2360  0.428
2015 McNeel DG, Chen YH, Gulley JL, Dwyer AJ, Madan RA, Carducci MA, DiPaola RS. Randomized Phase II Trial of Docetaxel with or without PSA-TRICOM Vaccine in Patients with Castrate-Resistant Metastatic Prostate Cancer: A Trial of the ECOG-ACRIN Cancer Research Group (E1809). Human Vaccines & Immunotherapeutics. 0. PMID 26111351 DOI: 10.1080/21645515.2015.1062190  0.548
2015 Rekoske BT, Smith HA, Olson BM, Maricque BB, McNeel DG. PD-1 or PD-L1 Blockade Restores Antitumor Efficacy Following SSX2 Epitope-Modified DNA Vaccine Immunization. Cancer Immunology Research. PMID 26041735 DOI: 10.1158/2326-6066.Cir-14-0206  0.791
2015 Gulley JL, Madan RA, Singh H, Gray TE, Trager JB, Sheikh NA, McCoy C, McNeel DG. The impact of age on sipuleucel-T-induced immune responses. Journal of Clinical Oncology. 33: e16009-e16009. DOI: 10.1200/Jco.2015.33.15_Suppl.E16009  0.428
2015 Choueiri TK, Fishman MN, Escudier B, McDermott DF, Kluger HM, Stadler WM, Perez-Gracia JL, McNeel DG, Curti BD, Harrison MR, Plimack ER, Appleman LJ, Fong L, Drake CG, Young TC, et al. Immunomodulatory activity of nivolumab in metastatic renal cell carcinoma (mRCC): Association of biomarkers with clinical outcomes. Journal of Clinical Oncology. 33: 4500-4500. DOI: 10.1200/Jco.2015.33.15_Suppl.4500  0.353
2015 Morishima C, McNeel DG, Patel MR, Kohrt HE, Waldmann TA, Thompson JA, Conlon KC, Sondel PM, Wakelee HA, Apodaca MC, Fling SP, Disis ML, Creekmore SP, Miller JS. CITN11-02 interim trial results: subcutaneous administration of recombinant human IL-15 (rhIL-15) is associated with expansion of peripheral blood CD56+ NK cells and CD8+ T cells Journal For Immunotherapy of Cancer. 3. DOI: 10.1186/2051-1426-3-S2-P203  0.327
2015 Colluru VT, McNeel DG. Abstract 2502: Immunization with minicircle and mini-intronic DNA vectors induce LAG-3 expressing CD8+ T cells and inferior anti-tumor responses Cancer Research. 75: 2502-2502. DOI: 10.1158/1538-7445.Am2015-2502  0.496
2015 Zahm CD, McNeel D. Abstract 2501: Vaccination using epitopes with higher MHC class I affinity elicits CD8+ T cells with increased PD-1 expression Cancer Research. 75: 2501-2501. DOI: 10.1158/1538-7445.Am2015-2501  0.535
2015 Rekoske BT, Olson BM, McNeel DG. Abstract 243: Expression of T-cell checkpoint ligands on circulating tumor cells is modulated following treatment of patients with an anti-tumor DNA vaccine Cancer Research. 75: 243-243. DOI: 10.1158/1538-7445.Am2015-243  0.566
2015 Bloom JE, McNeel DG. Abstract 1423: SSX-2 expression and function in metastatic prostate cancer Cancer Research. 75: 1423-1423. DOI: 10.1158/1538-7445.Am2015-1423  0.502
2015 Rekoske BT, Colluru VT, McNeel DG. Abstract CN04-03: DNA vaccines as treatment for prostate cancer - understanding mechanisms of resistance Molecular Cancer Therapeutics. 14. DOI: 10.1158/1535-7163.Targ-15-Cn04-03  0.619
2014 Choueiri T, Fishman MN, Escudier B, Kim JJ, Kluger H, Stadler WM, Perez-Garcia JL, McNeel D, Curti B, Harrison MR, Plimack ER, Appleman L, Fong L, Drake CG, Cohen L, et al. 1051PDIMMUNOMODULATORY ACTIVITY OF NIVOLUMAB IN PREVIOUSLY TREATED AND UNTREATED METASTATIC RENAL CELL CARCINOMA (MRCC): BIOMARKER-BASED RESULTS FROM A RANDOMIZED CLINICAL TRIAL. Annals of Oncology : Official Journal of the European Society For Medical Oncology. 25: iv362. PMID 28171273 DOI: 10.1093/Annonc/Mdu342.4  0.325
2014 McNeel DG, Gardner TA, Higano CS, Kantoff PW, Small EJ, Wener MH, Sims RB, DeVries T, Sheikh NA, Dreicer R. A transient increase in eosinophils is associated with prolonged survival in men with metastatic castration-resistant prostate cancer who receive sipuleucel-T. Cancer Immunology Research. 2: 988-99. PMID 25189164 DOI: 10.1158/2326-6066.Cir-14-0073  0.473
2014 McNeel DG, Becker JT, Eickhoff JC, Johnson LE, Bradley E, Pohlkamp I, Staab MJ, Liu G, Wilding G, Olson BM. Real-time immune monitoring to guide plasmid DNA vaccination schedule targeting prostatic acid phosphatase in patients with castration-resistant prostate cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 20: 3692-704. PMID 24850844 DOI: 10.1158/1078-0432.Ccr-14-0169  0.816
2014 Smith HA, Rekoske BT, McNeel DG. DNA vaccines encoding altered peptide ligands for SSX2 enhance epitope-specific CD8+ T-cell immune responses. Vaccine. 32: 1707-15. PMID 24492013 DOI: 10.1016/J.Vaccine.2014.01.048  0.81
2014 Morishima C, McNeel DG, Patel MR, Kohrt H, Waldmann TA, Thompson JA, Conlon K, M Sondel P, Wakelee H, Disis ML, Creekmore SP, Miller JS. CITN11-02 interim trial results: subcutaneous administration of recombinant human IL-15 (rhil-15) is associated with robust expansion of peripheral blood CD56+ NK cells Journal For Immunotherapy of Cancer. 2. DOI: 10.1186/2051-1426-2-S3-P80  0.329
2013 Becker JT, McNeel DG. Presence of antigen-specific somatic allelic mutations and splice variants do not predict for immunological response to genetic vaccination. Journal For Immunotherapy of Cancer. 1: 2. PMID 24764533 DOI: 10.1186/2051-1426-1-2  0.752
2013 Colluru VT, Johnson LE, Olson BM, McNeel DG. Preclinical and clinical development of DNA vaccines for prostate cancer. Urologic Oncology. PMID 24332642 DOI: 10.1016/J.Urolonc.2013.09.014  0.576
2013 Johnson LE, Becker JT, Dubovsky JA, Olson BM, McNeel DG. Prostate carcinoma in transgenic Lewis rats - a tumor model for evaluation of immunological treatments. Chinese Clinical Oncology. 2. PMID 24324949 DOI: 10.3978/J.Issn.2304-3865.2012.11.06  0.787
2013 Lang JM, Wallace M, Becker JT, Eickhoff JC, Buehring B, Binkley N, Staab MJ, Wilding G, Liu G, Malkovsky M, McNeel DG. A randomized phase II trial evaluating different schedules of zoledronic acid on bone mineral density in patients with prostate cancer beginning androgen deprivation therapy. Clinical Genitourinary Cancer. 11: 407-15. PMID 23835291 DOI: 10.1016/J.Clgc.2013.04.029  0.743
2013 Casavant BP, Mosher R, Warrick JW, Maccoux LJ, Berry SM, Becker JT, Chen V, Lang JM, McNeel DG, Beebe DJ. A negative selection methodology using a microfluidic platform for the isolation and enumeration of circulating tumor cells. Methods (San Diego, Calif.). 64: 137-43. PMID 23806645 DOI: 10.1016/J.Ymeth.2013.05.027  0.683
2013 Olson BM, McNeel DG. Monitoring regulatory immune responses in tumor immunotherapy clinical trials. Frontiers in Oncology. 3: 109. PMID 23653893 DOI: 10.3389/Fonc.2013.00109  0.405
2013 Olson BM, Johnson LE, McNeel DG. The androgen receptor: a biologically relevant vaccine target for the treatment of prostate cancer. Cancer Immunology, Immunotherapy : Cii. 62: 585-96. PMID 23108626 DOI: 10.1007/S00262-012-1363-9  0.619
2013 Cetnar J, Wilding G, McNeel D, LoConte NK, McFarland TA, Eickhoff J, Liu G. A phase 1/1b study of satraplatin (JM-216) in combination with docetaxel in patients with advanced solid tumors and metastatic castrate-resistant prostate cancer. Urologic Oncology. 31: 436-41. PMID 21481618 DOI: 10.1016/J.Urolonc.2011.02.007  0.471
2013 Bloom JE, McNeel DG. SSX expression and function in prostate cancer Journal For Immunotherapy of Cancer. 1. DOI: 10.1186/2051-1426-1-S1-P47  0.486
2013 Rekoske B, Smith HA, McNeel DG. Epitope optimization of a DNA vaccine targeting SSX-2 leads to PD-1 upregulation on antigen-specific CD8 T cells and PD-L1 upregulation on tumor cells Journal For Immunotherapy of Cancer. 1. DOI: 10.1186/2051-1426-1-S1-P233  0.798
2013 Colluru VT, McNeel DG. B lymphocyte mediated antigen presentation of plasmid DNA Journal For Immunotherapy of Cancer. 1. DOI: 10.1186/2051-1426-1-S1-P204  0.526
2013 McNeel D, Fasso M, Johnson L, Lemmens E, Hanson B, Lauer P, Bodovitz S, Drake C, Brockstedt DG. Abstract 2837: Combined targeting of antigens expressed in prostate cancer and prostate stem cells using Listeria-based cancer vaccines for the treatment of prostate cancer. Cancer Research. 73: 2837-2837. DOI: 10.1158/1538-7445.Am2013-2837  0.661
2012 McNeel DG, Becker JT, Johnson LE, Olson BM. DNA Vaccines for Prostate Cancer. Current Cancer Therapy Reviews. 8: 254-263. PMID 24587772 DOI: 10.2174/157339412804143113  0.806
2012 Bruce JY, Lang JM, McNeel DG, Liu G. Current controversies in the management of biochemical failure in prostate cancer. Clinical Advances in Hematology & Oncology : H&O. 10: 716-22. PMID 23271258  0.39
2012 Johnson LE, Frye TP, McNeel DG. Immunization with a prostate cancer xenoantigen elicits a xenoantigen epitope-specific T-cell response. Oncoimmunology. 1: 1546-1556. PMID 23264901 DOI: 10.4161/Onci.22564  0.525
2012 Bloom JE, McNeel DG, Olson BM. Vaccination using peptides spanning the SYT-SSX tumor-specific translocation. Expert Review of Vaccines. 11: 1401-4. PMID 23252384 DOI: 10.1586/Erv.12.122  0.483
2012 Olson BM, McNeel DG. Antigen loss and tumor-mediated immunosuppression facilitate tumor recurrence. Expert Review of Vaccines. 11: 1315-7. PMID 23249231 DOI: 10.1586/Erv.12.107  0.44
2012 Olson BM, Jankowska-Gan E, Becker JT, Vignali DA, Burlingham WJ, McNeel DG. Human prostate tumor antigen-specific CD8+ regulatory T cells are inhibited by CTLA-4 or IL-35 blockade. Journal of Immunology (Baltimore, Md. : 1950). 189: 5590-601. PMID 23152566 DOI: 10.4049/Jimmunol.1201744  0.763
2012 Johnson LE, McNeel DG. Identification of prostatic acid phosphatase (PAP) specific HLA-DR1-restricted T-cell epitopes. The Prostate. 72: 730-40. PMID 22529020 DOI: 10.1002/Pros.21477  0.627
2012 Morse MD, McNeel DG. T cells localized to the androgen-deprived prostate are TH1 and TH17 biased. The Prostate. 72: 1239-47. PMID 22213030 DOI: 10.1002/Pros.22476  0.778
2012 McNeel DG, Smith HA, Eickhoff JC, Lang JM, Staab MJ, Wilding G, Liu G. Phase I trial of tremelimumab in combination with short-term androgen deprivation in patients with PSA-recurrent prostate cancer. Cancer Immunology, Immunotherapy : Cii. 61: 1137-47. PMID 22210552 DOI: 10.1007/S00262-011-1193-1  0.813
2012 Zabransky DJ, Smith HA, Thoburn CJ, Zahurak M, Keizman D, Carducci M, Eisenberger MA, McNeel DG, Drake CG, Antonarakis ES. Lenalidomide modulates IL-8 and anti-prostate antibody levels in men with biochemically recurrent prostate cancer. The Prostate. 72: 487-98. PMID 21748755 DOI: 10.1002/Pros.21449  0.796
2012 Drake CG, Fishman MN, Curti BD, Kim JJ, Stadler WM, McNeel DG, Choueiri TK, Redman B, Hudes GR, Jure-Kunkel M, McDonald D, Gupta AK, Pathak AK, Wigginton J, Sznol M. An exploratory study to investigate the immunomodulatory activity of BMS-936558 in patients with metastatic clear-cell renal cell carcinoma. Journal of Clinical Oncology. 30: TPS2613-TPS2613. DOI: 10.1200/Jco.2012.30.15_Suppl.Tps2613  0.401
2012 McNeel DG, Lin DW, Gardner T, Sheikh NA, Whitmore JB, Sims RB, Dreicer R. Correlation of increased eosinophil count following sipuleucel-T treatment with outcome in patients (pts) with metastatic castrate-resistant prostate cancer (mCRPC). Journal of Clinical Oncology. 30: 4650-4650. DOI: 10.1200/Jco.2012.30.15_Suppl.4650  0.387
2012 Powers J, Sahakian E, Dubovsky JA, Farnum T, Berchmans E, McNeel DG, Skikne BS, MacBeth KJ, Komrokji RS, Pinilla-Ibarz J. Inducible Expression of Cancer Testis Antigens in Myelodysplastic Syndrome (MDS) Patients Following Treatment with an Oral 5-Azacytidine Blood. 120: 3828-3828. DOI: 10.1182/Blood.V120.21.3828.3828  0.426
2012 Becker JT, McNeel DG. Abstract 5384: Frequency of gene allelic variants of the PAP prostate tumor antigen and association with immune response following antigen-specific genetic vaccination Cancer Research. 72: 5384-5384. DOI: 10.1158/1538-7445.Am2012-5384  0.784
2012 Casavant BP, Lang J, Berry SM, Maccoux L, McNeel D, Beebe DJ. Abstract 2373: An integrated approach for isolating CTCs to enable the interrogation of cellular heterogeneity using IFAST Cancer Research. 72: 2373-2373. DOI: 10.1158/1538-7445.Am2012-2373  0.35
2011 Lang JM, Eickhoff JC, Binkley NC, Staab MJ, Liu G, Wilding G, McNeel DG. Randomized phase II trial evaluating different schedules of zoledronic acid administration on bone mineral density in patients with stage D prostate cancer beginning androgen deprivation. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 4643. PMID 28023932 DOI: 10.1200/Jco.2011.29.15_Suppl.4643  0.438
2011 Lang JM, Staab MJ, Liu G, Wilding G, McNeel DG. Phase I dose-escalation trial of tremelimumab in combination with bicalutamide in patients with recurrent prostate cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 174. PMID 27968439 DOI: 10.1200/Jco.2011.29.7_Suppl.174  0.542
2011 Olson BM, McNeel DG. Sipuleucel-T: immunotherapy for advanced prostate cancer. Open Access Journal of Urology. 3: 49-60. PMID 24198636 DOI: 10.2147/Oaju.S13069  0.572
2011 Smith HA, McNeel DG. Vaccines targeting the cancer-testis antigen SSX-2 elicit HLA-A2 epitope-specific cytolytic T cells. Journal of Immunotherapy (Hagerstown, Md. : 1997). 34: 569-80. PMID 21904219 DOI: 10.1097/Cji.0B013E31822B5B1D  0.812
2011 Smith HA, Cronk RJ, Lang JM, McNeel DG. Expression and immunotherapeutic targeting of the SSX family of cancer-testis antigens in prostate cancer. Cancer Research. 71: 6785-95. PMID 21880588 DOI: 10.1158/0008-5472.Can-11-2127  0.827
2011 Lang JM, Kaikobad MR, Wallace M, Staab MJ, Horvath DL, Wilding G, Liu G, Eickhoff JC, McNeel DG, Malkovsky M. Pilot trial of interleukin-2 and zoledronic acid to augment γδ T cells as treatment for patients with refractory renal cell carcinoma. Cancer Immunology, Immunotherapy : Cii. 60: 1447-60. PMID 21647691 DOI: 10.1007/S00262-011-1049-8  0.355
2011 Olson BM, McNeel DG. CD8+ T cells specific for the androgen receptor are common in patients with prostate cancer and are able to lyse prostate tumor cells. Cancer Immunology, Immunotherapy : Cii. 60: 781-92. PMID 21350948 DOI: 10.1007/S00262-011-0987-5  0.557
2011 Smith HA, Maricque BB, Eberhardt J, Petersen B, Gulley JL, Schlom J, McNeel DG. IgG responses to tissue-associated antigens as biomarkers of immunological treatment efficacy. Journal of Biomedicine & Biotechnology. 2011: 454861. PMID 21197272 DOI: 10.1155/2011/454861  0.831
2011 Maricque BB, Eickhoff JC, McNeel DG. Antibody responses to prostate-associated antigens in patients with prostatitis and prostate cancer. The Prostate. 71: 134-46. PMID 20632317 DOI: 10.1002/Pros.21229  0.58
2011 Powers J, Padron E, Dubovsky J, Berchmans E, Farnum T, Bai F, Sahakian E, Ahmed J, Komrokji RS, Lancet JE, List AF, McNeel DG, Dessureault S, Antonia S, Sotomayor EM, et al. Enhanced Immunological Responses Following K562/GM-CSF/CD40L Vaccine Plus Lenalidomide in High-Risk Myelodysplastic Syndrome Blood. 118: 1725-1725. DOI: 10.1182/Blood.V118.21.1725.1725  0.46
2011 Smith HA, Cronk RJ, Lang JM, McNeel DG. Abstract A66: Expression and immunotherapeutic targeting of the SSX family of cancer-testis antigens in prostate cancer Cancer Research. 71. DOI: 10.1158/1538-7445.Fbcr11-A66  0.605
2010 Smith HA, McNeel DG. The SSX family of cancer-testis antigens as target proteins for tumor therapy. Clinical & Developmental Immunology. 2010: 150591. PMID 20981248 DOI: 10.1155/2010/150591  0.782
2010 Gao JJ, Maricque BB, Morse MD, Huang W, McNeel DG. Identification of autoantibodies in a patient with testicular cancer and concurrent inflammatory bowel disease. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 28: e680-3. PMID 20805455 DOI: 10.1200/Jco.2010.30.2893  0.684
2010 Alam S, McNeel DG. DNA vaccines for the treatment of prostate cancer. Expert Review of Vaccines. 9: 731-45. PMID 20624047 DOI: 10.1586/Erv.10.64  0.612
2010 Becker JT, Olson BM, Johnson LE, Davies JG, Dunphy EJ, McNeel DG. DNA vaccine encoding prostatic acid phosphatase (PAP) elicits long-term T-cell responses in patients with recurrent prostate cancer. Journal of Immunotherapy (Hagerstown, Md. : 1997). 33: 639-47. PMID 20551832 DOI: 10.1097/Cji.0B013E3181Dda23E  0.819
2010 Morse MD, McNeel DG. Prostate cancer patients on androgen deprivation therapy develop persistent changes in adaptive immune responses. Human Immunology. 71: 496-504. PMID 20153396 DOI: 10.1016/J.Humimm.2010.02.007  0.799
2010 Olson BM, Frye TP, Johnson LE, Fong L, Knutson KL, Disis ML, McNeel DG. HLA-A2-restricted T-cell epitopes specific for prostatic acid phosphatase. Cancer Immunology, Immunotherapy : Cii. 59: 943-53. PMID 20140431 DOI: 10.1007/S00262-010-0820-6  0.532
2010 Stewart FP, dela Rosa CP, Sheikh NA, McNeel DG, Frohlich MW, Urdal DL, Provost NM. Correlation between product parameters and overall survival in three trials of sipuleucel-T, an autologous active cellular immunotherapy for the treatment of prostate cancer. Journal of Clinical Oncology. 28: 4552-4552. DOI: 10.1200/JCO.2010.28.15_SUPPL.4552  0.371
2010 McNeel DG. Reply to M.R. Smith et al Journal of Clinical Oncology. 28: e59-e59. DOI: 10.1200/Jco.2009.26.3459  0.52
2010 Maricque BB, McNeel DG. Abstract 5591: Detection of autoantibody responses to prostate cancer-associated antigens following treatment of patients with androgen deprivation therapy Cancer Research. 70: 5591-5591. DOI: 10.1158/1538-7445.Am10-5591  0.623
2010 Becker JT, Johnson LE, McNeel DG. Abstract 5584: DNA vaccine encoding prostatic acid phosphatase (PAP) elicits long-term T-cell responses in patients with recurrent prostate cancer Cancer Research. 70: 5584-5584. DOI: 10.1158/1538-7445.Am10-5584  0.809
2010 McNeel DG, Jankowska-Gan E, Burlingham WJ. Abstract 5581: Antigen-specific CTLA-4-regulated T-cell responses elicited in patients with prostate cancer treated by DNA immunization Cancer Research. 70: 5581-5581. DOI: 10.1158/1538-7445.Am10-5581  0.615
2010 Olson BM, Johnson LE, McNeel DG. Abstract 2404: A DNA vaccine encoding the androgen receptor ligand binding domain elicits anti-tumor immune responses in vivo Cancer Research. 70: 2404-2404. DOI: 10.1158/1538-7445.Am10-2404  0.62
2010 Smith HA, McNeel DG. Abstract 2397: SSX-2 vaccines with enhanced MHC class I binding epitopes elicit anti-prostate tumor CTL Cancer Research. 70: 2397-2397. DOI: 10.1158/1538-7445.Am10-2397  0.559
2010 Morse M, McNeel D. Androgen Deprivation Induces a Prostate Localized Adaptive Response in the Lewis Rat Clinical Immunology. 135: S98. DOI: 10.1016/J.Clim.2010.03.295  0.734
2009 Lang JM, Andrei AC, McNeel DG. Prioritization of cancer antigens: keeping the target in sight. Expert Review of Vaccines. 8: 1657-61. PMID 19943761 DOI: 10.1586/Erv.09.134  0.506
2009 McNeel DG, Dunphy EJ, Davies JG, Frye TP, Johnson LE, Staab MJ, Horvath DL, Straus J, Alberti D, Marnocha R, Liu G, Eickhoff JC, Wilding G. Safety and immunological efficacy of a DNA vaccine encoding prostatic acid phosphatase in patients with stage D0 prostate cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 27: 4047-54. PMID 19636017 DOI: 10.1200/Jco.2008.19.9968  0.617
2009 Hou Y, DeVoss J, Dao V, Kwek S, Simko JP, McNeel DG, Anderson MS, Fong L. An aberrant prostate antigen-specific immune response causes prostatitis in mice and is associated with chronic prostatitis in humans. The Journal of Clinical Investigation. 119: 2031-41. PMID 19603556 DOI: 10.1172/Jci38332  0.534
2009 Olson BM, McNeel DG. Methods for constructing and evaluating antitumor DNA vaccines. Methods in Molecular Biology (Clifton, N.J.). 542: 211-43. PMID 19565905 DOI: 10.1007/978-1-59745-561-9_12  0.473
2009 Dubovsky JA, McNeel DG, Powers JJ, Gordon J, Sotomayor EM, Pinilla-Ibarz JA. Treatment of chronic lymphocytic leukemia with a hypomethylating agent induces expression of NXF2, an immunogenic cancer testis antigen. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 15: 3406-15. PMID 19401350 DOI: 10.1182/Blood.V112.11.4207.4207  0.466
2009 Fong L, Kwek SS, O'Brien S, Kavanagh B, McNeel DG, Weinberg V, Lin AM, Rosenberg J, Ryan CJ, Rini BI, Small EJ. Potentiating endogenous antitumor immunity to prostate cancer through combination immunotherapy with CTLA4 blockade and GM-CSF. Cancer Research. 69: 609-15. PMID 19147575 DOI: 10.1158/0008-5472.Can-08-3529  0.511
2008 Goodell V, McNeel D, Disis ML. His-tag ELISA for the detection of humoral tumor-specific immunity. Bmc Immunology. 9: 23. PMID 18510754 DOI: 10.1186/1471-2172-9-23  0.431
2008 Attia S, Eickhoff J, Wilding G, McNeel D, Blank J, Ahuja H, Jumonville A, Eastman M, Shevrin D, Glode M, Alberti D, Staab MJ, Horvath D, Straus J, Marnocha R, et al. Randomized, double-blinded phase II evaluation of docetaxel with or without doxercalciferol in patients with metastatic, androgen-independent prostate cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 14: 2437-43. PMID 18413835 DOI: 10.1158/1078-0432.Ccr-07-4274  0.458
2008 Fong L, Kwek S, Kavanagh B, O'Brien S, McNeel D, Weinberg V, Rini B, Small EJ. Abstract 2539: CTLA-4 blockade for hormone refractory prostate cancer: Dose-dependent induction of CD8+ T cell activation and clinical responses Cancer Research. 68: 2539-2539. DOI: 10.1158/1538-7445.Am2008-2539  0.469
2007 Lalich M, McNeel DG, Wilding G, Liu G. Endothelin receptor antagonists in cancer therapy. Cancer Investigation. 25: 785-94. PMID 18058475 DOI: 10.1080/07357900701522588  0.449
2007 Ward JE, McNeel DG. GVAX: an allogeneic, whole-cell, GM-CSF-secreting cellular immunotherapy for the treatment of prostate cancer. Expert Opinion On Biological Therapy. 7: 1893-902. PMID 18034654 DOI: 10.1517/14712598.7.12.1893  0.56
2007 Dubovsky JA, McNeel DG. Inducible expression of a prostate cancer-testis antigen, SSX-2, following treatment with a DNA methylation inhibitor. The Prostate. 67: 1781-90. PMID 17929270 DOI: 10.1002/Pros.20665  0.577
2007 Dubovsky JA, Albertini MR, McNeel DG. MAD-CT-2 identified as a novel melanoma cancer-testis antigen using phage immunoblot analysis. Journal of Immunotherapy (Hagerstown, Md. : 1997). 30: 675-83. PMID 17893560 DOI: 10.1097/Cji.0B013E3180De4D19  0.465
2007 Olson BM, McNeel DG. Antibody and T-cell responses specific for the androgen receptor in patients with prostate cancer. The Prostate. 67: 1729-39. PMID 17879963 DOI: 10.1002/Pros.20652  0.557
2007 Kipp RT, McNeel DG. Immunotherapy for prostate cancer - recent progress in clinical trials. Clinical Advances in Hematology & Oncology : H&O. 5: 465-74, 477-9. PMID 17679921  0.449
2007 McNeel DG. Prostate cancer immunotherapy. Current Opinion in Urology. 17: 175-81. PMID 17414515 DOI: 10.1097/Mou.0B013E3280Eb10Eb  0.566
2007 Agus DB, Sweeney CJ, Morris MJ, Mendelson DS, McNeel DG, Ahmann FR, Wang J, Derynck MK, Ng K, Lyons B, Allison DE, Kattan MW, Scher HI. Efficacy and safety of single-agent pertuzumab (rhuMAb 2C4), a human epidermal growth factor receptor dimerization inhibitor, in castration-resistant prostate cancer after progression from taxane-based therapy. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 25: 675-81. PMID 17308272 DOI: 10.1200/Jco.2006.07.0649  0.301
2007 McNeel DG. Cellular immunotherapies for prostate cancer. Biomedicine & Pharmacotherapy = BioméDecine & PharmacothéRapie. 61: 315-22. PMID 17306498 DOI: 10.1016/J.Biopha.2006.12.006  0.531
2007 Johnson LE, Frye TP, Chinnasamy N, Chinnasamy D, McNeel DG. Plasmid DNA vaccine encoding prostatic acid phosphatase is effective in eliciting autologous antigen-specific CD8+ T cells. Cancer Immunology, Immunotherapy : Cii. 56: 885-95. PMID 17102977 DOI: 10.1007/S00262-006-0241-8  0.586
2006 Mooney CJ, Dunphy EJ, Stone B, McNeel DG. Identification of autoantibodies elicited in a patient with prostate cancer presenting as dermatomyositis. International Journal of Urology : Official Journal of the Japanese Urological Association. 13: 211-7. PMID 16643611 DOI: 10.1111/J.1442-2042.2006.01263.X  0.472
2006 Hoeppner LH, Dubovsky JA, Dunphy EJ, McNeel DG. Humoral immune responses to testis antigens in sera from patients with prostate cancer. Cancer Immunity. 6: 1. PMID 16401063  0.55
2006 Johnson LE, Frye TP, Arnot AR, Marquette C, Couture LA, Gendron-Fitzpatrick A, McNeel DG. Safety and immunological efficacy of a prostate cancer plasmid DNA vaccine encoding prostatic acid phosphatase (PAP). Vaccine. 24: 293-303. PMID 16115700 DOI: 10.1016/J.Vaccine.2005.07.074  0.582
2006 Malkovsky M, McNeel DG, Wallace M, Schell K, Wilding G, Eikhoff J, Staab MJ, Horvath D, Straus J, Liu G. Use of zoledronic acid (ZA) and interleukin-2 (IL-2) to activate and expand Vγ9Vδ2 T cells for therapeutic use in patients with metastatic renal cell carcinoma (mRCC) Journal of Clinical Oncology. 24: 14607-14607. DOI: 10.1200/Jco.2006.24.18_Suppl.14607  0.366
2006 McNeel DG, Dunphy EJ, Johnson LE, Frye TP, Staab MJ, Horvath DL, Straus J, Alberti D, Liu G, Wilding G. A plasmid DNA vaccine encoding prostatic acid phosphatase (PAP) elicits antigen-specific T cells in patients with stage D0 prostate cancer Journal of Clinical Oncology. 24: 14570-14570. DOI: 10.1200/Jco.2006.24.18_Suppl.14570  0.635
2006 Dunphy EJ, Johnson LE, Olson BM, Frye TP, McNeel DG. New approaches to identification of antigenic candidates for future prostate cancer immunotherapy Update On Cancer Therapeutics. 1: 273-284. DOI: 10.1016/J.Uct.2006.05.011  0.562
2005 Agus DB, Sweeney CJ, Morris M, Mendelson D, McNeel DG, Ahmann F, Wang J, Derynck MK, Kattan MW, Scher HI. Efficacy and safety of single agent pertuzumab (rhuMAb 2C4), a HER dimerization inhibitor, in hormone refractory prostate cancer after failure of taxane-based therapy. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 23: 4624. PMID 27947001 DOI: 10.1200/Jco.2005.23.16_Suppl.4624  0.353
2005 Zlotocha S, Staab MJ, Horvath D, Straus J, Dobratz J, Oliver K, Wasielewski S, Alberti D, Liu G, Wilding G, Eickhoff J, McNeel DG. A phase I study of a DNA vaccine targeting prostatic Acid phosphatase in patients with stage D0 prostate cancer. Clinical Genitourinary Cancer. 4: 215-8. PMID 16425992 DOI: 10.3816/Cgc.2005.N.036  0.561
2005 McNeel DG, Eickhoff J, Lee FT, King DM, Alberti D, Thomas JP, Friedl A, Kolesar J, Marnocha R, Volkman J, Zhang J, Hammershaimb L, Zwiebel JA, Wilding G. Phase I trial of a monoclonal antibody specific for alphavbeta3 integrin (MEDI-522) in patients with advanced malignancies, including an assessment of effect on tumor perfusion. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 11: 7851-60. PMID 16278408 DOI: 10.1158/1078-0432.Ccr-05-0262  0.376
2005 McNeel DG. Prostate cancer antigens and vaccines, preclinical developments. Cancer Chemotherapy and Biological Response Modifiers. 22: 247-61. PMID 16110615 DOI: 10.1016/S0921-4410(04)22011-7  0.6
2005 Dunphy EJ, McNeel DG. Antigen-specific IgG elicited in subjects with prostate cancer treated with flt3 ligand. Journal of Immunotherapy (Hagerstown, Md. : 1997). 28: 268-75. PMID 15838384 DOI: 10.1097/01.Cji.0000158853.15664.0C  0.565
2005 McNeel DG, Malkovsky M. Immune-based therapies for prostate cancer. Immunology Letters. 96: 3-9. PMID 15585302 DOI: 10.1016/J.Imlet.2004.06.009  0.535
2004 Hegeman RB, Liu G, Wilding G, McNeel DG. Newer therapies in advanced prostate cancer. Clinical Prostate Cancer. 3: 150-6. PMID 15636681 DOI: 10.3816/Cgc.2004.N.025  0.499
2004 Dunphy EJ, Eickhoff JC, Muller CH, Berger RE, McNeel DG. Identification of antigen-specific IgG in sera from patients with chronic prostatitis. Journal of Clinical Immunology. 24: 492-502. PMID 15359108 DOI: 10.1023/B:Joci.0000040920.96065.5A  0.558
2003 Disis ML, Shiota FM, McNeel DG, Knutson KL. Soluble cytokines can act as effective adjuvants in plasmid DNA vaccines targeting self tumor antigens Immunobiology. 207: 179-186. PMID 12777059 DOI: 10.1078/0171-2985-00230  0.407
2003 McNeel DG, Knutson KL, Schiffman K, Davis DR, Caron D, Disis ML. Pilot study of an HLA-A2 peptide vaccine using flt3 ligand as a systemic vaccine adjuvant. Journal of Clinical Immunology. 23: 62-72. PMID 12645861 DOI: 10.1023/A:1021904432489  0.433
2001 McNeel DG, Nguyen LD, Ellis WJ, Higano CS, Lange PH, Disis ML. Naturally occurring prostate cancer antigen-specific T cell responses of a Th1 phenotype can be detected in patients with prostate cancer. The Prostate. 47: 222-9. PMID 11351352 DOI: 10.1002/PROS.1066  0.498
2001 Disis ML, Knutson KL, McNeel DG, Davis D, Schiffman K. Clinical Translation of Peptide-Based Vaccine Trials: The HER-2/neu Model Critical Reviews™ in Immunology. 21: 11. DOI: 10.1615/Critrevimmunol.V21.I1-3.170  0.418
2000 Disis ML, Knutson KL, Schiffman K, Rinn K, McNeel DG. Pre-existent immunity to the HER-2/neu oncogenic protein in patients with HER-2/neu overexpressing breast and ovarian cancer Breast Cancer Research and Treatment. 62: 245-252. PMID 11072789 DOI: 10.1023/A:1006438507898  0.36
2000 McNEEL DG, NGUYEN LD, STORER BE, VESSELLA R, LANGE PH, DISIS ML. ANTIBODY IMMUNITY TO PROSTATE CANCER ASSOCIATED ANTIGENS CAN BE DETECTED IN THE SERUM OF PATIENTS WITH PROSTATE CANCER Journal of Urology. 164: 1825-1829. DOI: 10.1016/S0022-5347(05)67114-5  0.479
1999 McNeel DG, Schiffman K, Disis ML. Immunization With Recombinant Human Granulocyte-Macrophage Colony-Stimulating Factor as a Vaccine Adjuvant Elicits Both a Cellular and Humoral Response to Recombinant Human Granulocyte-Macrophage Colony-Stimulating Factor Blood. 93: 2653-2659. DOI: 10.1182/BLOOD.V93.8.2653.408K07_2653_2659  0.356
Show low-probability matches.